Furthermore, preclinical results, including effects on PD-L1 regulation and reduced toxicity compared to combined HDAC and proteasome inhibitors, have yielded positive outcomes, emphasizing their potential in cancer therapy25,26. This evidence concerns the gene CD274 and cancer.